<DOC>
	<DOCNO>NCT03041766</DOCNO>
	<brief_summary>The clinical trial phase 2a design assess safety active ingredient ( protein + adjuvant ) secondarily immunogenicity healthy male adult 18 49 year age history infection intestinal urinary schistosomiasis , live Valley Senegal River , highly endemic area schistosomiasis . Two arm study test different dos GLA-SE adjuvant ( 2.5 5 μg ) . This phase IIA adult consider preliminary step safety start trial child endemic area S. mansoni S. haematobium , target population vaccine .</brief_summary>
	<brief_title>Study Safety Immune Response Sm14 Vaccine Adults Endemic Regions</brief_title>
	<detailed_description>A phase 2a trial , self-contained , open-label , randomize , dose-escalation study two parallel arm receive three ( 3 ) injection D0 , D28 , D56 ; group receive 50 μg Sm14 vaccine candidate solution , either combine 2.5µg GLA-SE first group 5µg second one adult live S. mansoni S. haematobium endemic area . Sm14 : recombinant protein produce yeast follow Good Manufacturing Practices ( GMP ) condition , present vial contain 0.55 ml solution Sm14 , 0.4 ml solution dilute 0.4 ml GLA ( Synthetic Glucopyranosyl lipid A ) intramuscular administration . Medical examination perform D0 ( injection , 1 hr 4 hr ) , safety evaluation 24 hr 48 hr , injection . Blood analysis : Liver function test - renal function test - blood count , W-1 inclusion , 7 day injection W13 W21 follow-up . Blood sample immune response analysis time injection , W12 W20 .</detailed_description>
	<mesh_term>Schistosomiasis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Adults , male , 18 49 year old ( inclusive ) time inclusion . Living one select village SaintLouis Region ( Senegal ) . Free obvious/severe health problem except schistosomiasis , establish clinical examination blood analysis , i.e . hematological exam , liver renal function test . Written inform consent participate obtain Treated 40mg/kg Praziquantel ( PZQ ) inclusion ( W5 W4 first injection ) case infection S. mansoni S. haematobium Residence area period study . Adult respond one inclusion criterion Current previous chronic administration ( defined 14 day ) immunosuppressive drug immunomodifying drug . Known hypersensitivity component Sm14 vaccine history allergic disease . Knowledge noninfectious chronic disease Acute disease time enrollment . Other condition opinion PI may potentially represent danger patient enrol . Non residence study area intent move study period</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Schistosomiasis</keyword>
	<keyword>Recombinant vaccine</keyword>
	<keyword>rSm14</keyword>
	<keyword>GLA-SE</keyword>
	<keyword>Fatty acid-binding protein ( FABP )</keyword>
	<keyword>Phase II Clinical Trial</keyword>
	<keyword>Senegal</keyword>
</DOC>